SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006435
Filing Date
2020-05-12
Accepted
2020-05-12 16:39:18
Documents
58
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20200331x10q.htm 10-Q 1429637
2 EX-10.1 btai-20200331ex101684770.htm EX-10.1 23098
3 EX-31.1 btai-20200331ex3113a1706.htm EX-31.1 23240
4 EX-31.2 btai-20200331ex312035d17.htm EX-31.2 22916
5 EX-32.1 btai-20200331ex321c14e1b.htm EX-32.1 12373
6 EX-32.2 btai-20200331ex322ad4b44.htm EX-32.2 10789
  Complete submission text file 0001558370-20-006435.txt   3948709

Data Files

Seq Description Document Type Size
7 EX-101.INS btai-20200331.xml EX-101.INS 507247
8 EX-101.SCH btai-20200331.xsd EX-101.SCH 32919
9 EX-101.CAL btai-20200331_cal.xml EX-101.CAL 32735
10 EX-101.DEF btai-20200331_def.xml EX-101.DEF 93242
11 EX-101.LAB btai-20200331_lab.xml EX-101.LAB 301839
12 EX-101.PRE btai-20200331_pre.xml EX-101.PRE 218002
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 20869629
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences